A rationale for targeting the P2X7 receptor in Coronavirus disease 19

Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid‐19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activa...

Full description

Saved in:
Bibliographic Details
Published in:British journal of pharmacology 2020-11, Vol.177 (21), p.4990-4994
Main Authors: Di Virgilio, Francesco, Tang, Yong, Sarti, Alba Clara, Rossato, Marco
Format: Article
Language:English
Subjects:
Animals
Betacoronavirus - isolation & purification
Coronavirus Infections - drug therapy
Coronavirus Infections - physiopathology
Coronavirus Infections - virology
Coronaviruses
COVID-19
Cytokine Release Syndrome - virology
Cytokine storm
Cytokines
Edema
Humans
Inflammation
Lymphocytes T
Macrophages
Macrophages - pathology
Morbidity
Pandemics
Pneumonia
Pneumonia, Viral - drug therapy
Pneumonia, Viral - physiopathology
Pneumonia, Viral - virology
Receptors, Purinergic P2X7 - drug effects
Receptors, Purinergic P2X7 - metabolism
Research Paper
Respiratory distress syndrome
Respiratory Distress Syndrome - drug therapy
Respiratory Distress Syndrome - virology
SARS-CoV-2
T-Lymphocytes - pathology
Themed Issue: Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid‐19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung oedema, inflammatory cell infiltration, and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid‐19‐associated severe pneumonia. Linked Articles This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc
ISSN:0007-1188
1476-5381
DOI:10.1111/bph.15138